Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24510146 | 0.95 | HPGD (0.48) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL29190839 | 0.88 | KDM4E (0.47) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL1575491 | 0.85 | GPR119 (0.47) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL7414887 | 0.83 | GPR119 (0.49) | KDM4EPKMHPGDGPR119FAAH | |
| SCHEMBL7983094 | 0.83 | KDM4E (0.44) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL7983288 | 0.82 | KDM4E (0.43) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL29052765 | 0.81 | HPGD (0.45) | KDM4EPKMHPGDEPHX1GPR119 | |
| SCHEMBL13537861 | 0.81 | HPGD (0.44) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL8502071 | 0.80 | DPP4 (0.43) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL12082 | 0.79 | HPGD (0.55) | KDM4EPKMHPGDRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | KDM4E 1998/4885PKM 2008/4885HPGD 669/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | KDM4E 1998/4885PKM 2008/4885HPGD 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.